Effect of phytoneering remedy BNO 2103 on the course of experimental exudative inflammation caused by different phlogogens

V. V. Chernykh*, I. A. Zupanets, S. K. Shebeko

National University of Pharmacy, Kharkiv, Ukraine

Kidney and urinary tract diseases play an important role in the disease distribution in most countries of the world. The pharmaceutical industry offers many means for the treatment and prevention of these diseases, but there is a trend toward a growing interest in herbal medicines, their empirical application and scientific study.

The aim of this research is to study anti-inflammatory properties of standardized herbal composition BNO 2103 in a model of paw inflammation in rats caused by different phlogogens to justify the use of it in the treatment of chronic kidney disease (CKD).

Materials and methods. The experimental study was performed using 90 male white outbred rats weighing 150–200 g, which were divided into 3 series of 30 animals each, each series included 3 groups. Inflammation of the paw was induced by subplantar administration of phlogogens – zymosan, histamine and serotonin. The study agent and the reference drug, diclofenac sodium, were administered intragastrically (i. g.) once. Edema was observed and recorded, and anti-inflammatory activity (AIA) was assessed in 0.5, 1.0, 2.0, 3.0 and 6.0 hours after phlogogen injection.

Results. BNO 2103 showed a remarkable anti-exudative effect in the model of zymosan and histamine edema, being significantly superior to diclofenac sodium. In the serotonin edema model, BNO 2103 was significantly superior to the comparator by the endpoints, showing the moderate but prolonged anti-exudative effect.

Conclusions. BNO 2103 has the significant anti-inflammatory effect, exerting an inhibitory effect on exudative inflammation caused by various phlogogens (zymosan, histamine, serotonin), mainly acting on the lipoxigenase pathway of arachidonic acid conversion, which is most likely due to the presence of flavonoids. This allows us to consider BNO 2103 as a promising drug for the treatment of CKD.

Key words: BNO 2103, herbal composition, anti-inflammatory properties, preclinical study.
Kidney and urinary tract diseases play an important role in the disease distribution in most countries of the world and are a crucial problem in the global health sector. The pharmaceutical industry offers many means for the treatment and prevention of these diseases, but there is a tendency to pay more attention to herbal medicines, their empirical application and scientific study.

The object of our study is a standardized herbal composition BNO 2103, which is an active pharmaceutical ingredient of the combined phytoengineering drug Canephron® N manufactured by Bionorica SE (Germany). The components of this herbal medicine have a complex pharmacodynamics, which is manifested in anti-inflammatory, antioxidant, antibacterial, diuretic, antispasmodic and analgesic effects [1]. These properties, along with a significant anti-inflammatory effect, allow Canephron® N to occupy a confident place among the drugs for correction of inflammatory processes in the urinary system. However, the registration of Canephron® N varies in different countries in terms of indications and dosage forms. For example, in the country of origin – Germany, as well as in Poland and Ukraine, the drug is officially declared for the use in the treatment of urinary tract inflammatory diseases, as well as for irrigation of the lower urinary tract, primary and secondary prevention of urolithiasis [1–3]. In Russia, the drug is registered with indications for the treatment of chronic infections of the bladder (cystitis) and kidneys (pyelonephritis), as well as non-infectious renal diseases (glomerulonephritis and interstitial nephritis) and urolithiasis [4]. It should be noted that in no country the drug is included in the treatment of chronic kidney disease (CKD), as there is a lack of evidence to consider such a prospect.

That is why, in our study, we have drawn attention to the problem of phytopharmacological correction of this disease, which poses a dramatic population threat – the incidence and mortality from CKD is growing every year. According to the Global Kidney Health Atlas 2019, the prevalence of this pathology in Ukraine is 18.18 % (95 % CI, 16.81–19.64) [5]. In our research, we have studied BNO 2103 in terms of influence on biochemical, histomorphological, immunohistochemical and functional indications of the kidneys, using a number of experimental models to comprehensively study its properties. CKD is a multifactorial disease with diverse etiopathogenesis, but inflammation is an integral part of many diseases from a CKD group. For this reason, we have given special attention to the study on the anti-inflammatory activity of the remedy, since without this the formation of the evidence base would be incomplete. Canephron® is already known as a remedy for the treatment of diseases from the CKD group with a significant inflammatory component, such as glomerulonephritis, pyelonephritis, interstitial nephritis [4], etc.

Therefore, it is advisable to continue this series of studies and investigate the anti-exudative properties of BNO 2103 in order to establish the embodying mechanisms of its anti-inflammatory effect, in particular, the influence on the pathways of arachidonic acid conversion. Given the following data, this contributes to the expansion of indications for the study drug use to empower patients and physicians to manage CKD. The long-term benefits of using BNO 2103 for the treatment of CKD is that the arsenal of drugs for the treatment of this nosological complex will be replenished with a herbal remedy with a sufficient evidence base, complex action, high efficiency and safety. The above characteristics will allow BNO 2103 to be included in the treatment profile of CKD at any stage of the disease with the expected effectiveness, enhancing patient compliance and doctor’s trust in this remedy.

**Aim**

We consider the standardized herbal composition BNO 2103 produced by Bionorica SE (Germany) as a promising agent for the pathogenetic treatment of CKD, therefore, the aim of the research is to study anti-inflammatory properties of BNO 2103 in a model of paw inflammation in rats caused by various phlogogens.

**Materials and methods**

An experimental study was performed using 90 white male outbred rats weighing 150–200 g, which were obtained from the vivarium of the Educational and Scientific Institute of Applied Pharmacy of the National University of Pharmacy (ESIApP NUPh, Kharkiv, Ukraine). Animals received a standard diet with unlimited access to water and were kept

---

**Key Words:** BNO 2103, standardized herbal composition, anti-inflammatory properties, phytomedicine, anti-inflammatory activity.
All studies have been carried out in accordance with the EU Council Directive 2010/63/EC in compliance with the laws, regulations and administrative provisions of the EU Member States concerning the protection of animals used for scientific purposes [8]. The experimental protocols were approved by the NUPh Bioethics Commission (Approval No. 2 dated November 4, 2019).

Test object BNO 2103 contains a mixture of extracts of centaury herb, rosemary leaves and lovage root in the form of a fine amorphous hygroscopic brown powder with a characteristic odor of medicinal plants. BNO 2103 is slightly soluble in water; thus, it was administered to animals in the form of an aqueous suspension prepared with a vehicle (carboxymethylcellulose 0.5 % + Tween-80 0.1 %), without prior grinding in a mortar. The appropriate suspension was mixed with Vortex V-1 Plus (Biosan, Latvia) immediately before administration to laboratory animals.

Diclofenac sodium, 25 mg in tablets was chosen as a reference drug as a known anti-inflammatory agent of the NSAID class [9]. Test samples of diclofenac sodium were administered as an aqueous suspension prepared with a vehicle and pre-grounding in a mortar. All samples were administered once intragastrically (i. g.) using a gastric tube.

During the study, the animals were weighed, labeled and divided into equivalent groups. Throughout the experiment, laboratory monitoring of animals, control of their body weight, food intake and behavior were performed.

The study of anti-inflammatory properties of BNO 2103 was performed on a model of experimental exudative inflammation in rats caused by different phlogogens [10,11]. All animals were divided into 3 series of 30 animals each, each series included 3 groups (n = 10):

- Group 1 – control pathology (CP) (untreated animals receiving vehicle).
- Group 2 – rats with paw edema treated with BNO 2103 i. g. at a dose of 33.0 mg/kg (corresponding to the recommended human dose extrapolated according to FDA recommendations [12]).
- Group 3 – rats with paw edema treated with diclofenac sodium i. g. at a dose of 8.0 mg/kg (ED50 for anti-inflammatory activity [13]).

The experiment was performed using 3 groups of animals per day. Rats were involved in the study by turn without delay so that the evaluation of each animal was performed at equal time intervals after the formation of pathology – 0.5, 1.0, 2.0, 3.0 and 6.0 hours.

At the beginning of the experiment, the initial volume (cm³) of the right hind paw was determined using a digital plethysmometer (IITC Life Science, USA).

After that, the test and reference drugs were administered once i. g. in the appropriate doses. Animals from the CP group received an equivalent amount of solvent i. g.

One hour later, all rats underwent inducing an aseptic exudative inflammation in the right hind paw by subplantar injection of 0.1 ml of various phlogogenic substances, such as: 2.0 % suspension of zymosan – for series I; 0.25 % histamine solution – for series II and 0.5 % serotonin solution – for series III.

The study results have shown an inflammatory reaction under the influence of zymosan in the CP group throughout the study. The highest degree of exudation – 44.5 % of the initial level, was registered 1 hour after the onset of inflammation, then the edema gradually decreased to 15.2 % in 6 hours (Fig. 1).

The greatest anti-exudative activity was shown by BNO 2103, which had an inhibitory effect on the development of edema with significant differences from the CP group up to 3 hours of observation, with the highest rate of AIA – 77.8 % which was recorded in 0.5 hours. In the range from 0.5 to 1.0 hour, the BNO 2103 AIA rate clearly turned negative dynamics, but the AIA rate decreased gradually in the subsequent points (Fig. 2). Diclofenac sodium also reduced (P < 0.05) the development of edema compared to the CP, but showed less activity, inhibiting exudation for up to 3 hours. At the same time, up to 2 hours, it was inferior (P < 0.05) to BNO 2103 in terms of AIA. At the peak of exudation at the point of 1 hour, its AIA was 42.3 % and 1.7 times lower than in the group of BNO 2103 (P < 0.05) (Fig. 2).

Thus, BNO 2103 showed the statistically significant anti-exudative effect in the model of zymosan edema, being reliably superior to diclofenac sodium.

The anti-exudative activity of BNO 2103 was studied in a model of histamine – induced paw edema in rats. The results are shown in Figs. 3, 4.
In the CP group, the most prominent exudation was observed 1 hour after administration – 32.0 % of a baseline. Then, the edema gradually decreased towards the end of the 6-hour observation (Fig. 3).

BNO 2103 showed the anti-exudative effect (P < 0.05) comparing to the CP group within 0.5, 1.0 and 3.0 hours after the injection of phlogogen. At the same time, the highest rate of AIA in this model – 44.1 %, was recorded in an hour of observations. Despite a very similar dynamics of edema development in the group of test and reference agents between 2 and 6 hours, the AIA rate differed significantly at the corresponding time points with clear benefits of BNO 2103 (Figs. 3, 4).

The reference drug diclofenac sodium showed a weak anti-exudative effect throughout the study and had differences from the CP group only at 1-hour point (P < 0.05). Also, at all points, it was inferior (P < 0.05) to BNO 2103 in terms of activity. At the time of the peak exudation (1 hour), its AIA was 8.9 %, which was 5.0 times lower than in the group of BNO 2103 (P < 0.05) (Fig. 4). The obtained data indicate that BNO 2103 has an expressed inhibitory influence on the pro-inflammatory effects of histamine, being significantly superior to diclofenac sodium due to the presence of biologically active substances in its composition and their effects.

**Effect of BNO 2103 on the course of serotonin-induced edema in rats.** The effect of BNO 2103 on the course of the paw edema caused by serotonin as one of the additional inflammatory mediators was also studied. The injection of serotonin in the CP group caused the development of edema, most prominent at 1- and 2-hour points, when the degree of exudation was 28.9 % and 28.0 % of the baseline, respectively (Fig. 5). Over time, its intensity gradually decreased. BNO 2103 showed a moderate anti-exudative effect, which was significant (P < 0.05) compared to the CP group in 1 hour after induction, with the highest level of AIA – 27.7 %. Then its activity was in the range of 20.1–17.2 % (Fig. 6).

Diclofenac sodium showed 1.6 times higher levels of AIA than BNO 2103 (P < 0.05), 1 hour after administration of serotonin (44.4 %). But, subsequently, it was inferior (P < 0.05) to BNO 2103 in 3 and 6 hours of observation. Moreover, BNO 2103 1.7 times exceeded the reference drug as to the AIA level in 3 hours, and 2.5 times – in 6 hours, indicating a remarkably prolonged anti-exudative effect in serotonin inflammation (Fig. 6). Thus, BNO 2103 performed well, compared to the reference drug due to the moderate but prolonged anti-exudative effect in contrast with significant but short-lived impact of diclofenac sodium, and was superior (P < 0.05) to it in terms of AIA levels at later observation points of 3 and 6 hours after phlogogen administration.

**Discussion**

There is no doubt that inflammation is an important link in the pathogenesis of CKD, especially in the case of its autoimmune or rheumatic origin, which leads to the destruction of membrane structures of nephrocytes, activation of proliferative processes and, consequently, the formation of renal failure (RF). The anti-inflammatory effect of drugs is one of the basic pharmacological effects underlying the organoprotective effect and, in particular, nephroprotective. This determines the feasibility of studying the anti-inflammatory
Effect of BNO 2103 on the course of serotonin-induced edema in rats. Data are presented as M ± SEM; *: P < 0.05 relating to the CP group; **: P < 0.05 relating to the BNO 2103 group.

**Fig. 5.**

AIA, %

Effect of BNO 2103 on the course of serotonin-induced edema in rats. Data are presented as M ± SEM; *: P < 0.05 relating to the CP group; **: P < 0.05 relating to the BNO 2103 group.

**Fig. 6.**

Properties of the agent proposed for the treatment of CKD in models of experimental inflammatory process.

For this purpose, models of zymosan, histamine and serotonin paw edema in rats were used, which were combined according to the principle of inflammation development mainly through the lipoxygenase pathway of arachidonic acid conversion. This has allowed us to assess the effect of the test object for the lipoxygenase pathway of arachidonic acid metabolism, as well as for the action of additional inflammatory mediators such as serotonin and histamine.

The results of the study on the anti-exudative effect of the combined herbal remedy BNO 2103 in models of paw edema in rats caused by different phlogogens (zymosan, histamine and serotonin) showed that the test drug had a variably expressed inhibitory effect on the development of exudation in all models. Due to the fact that BNO 2103 showed the highest level of activity in the model of zymosan-induced edema, it can be claimed that the most important in the mechanism of its anti-inflammatory effect is the ability to inhibit lipoxygenase pathway of arachidonic acid conversion and leukotriene formation. This is probably associated with the presence of flavonoids in its composition. There has also been demonstrated the ability of BNO 2103 to inhibit the pro-inflammatory action of histamine and serotonin, especially at the beginning of inflammation, which is also possibly related to its antileukotriene activity.

These pharmacological properties of BNO 2103 are determined by a complex of biologically active substances (flavonoids, phenolic acids, essential oils), which are contained in the plant material of the test drug – a mixture of century herb, rosemary leaves and lovage root [15]. It is important to note that BNO 2103 is a fixed composition of plant components and a special attention is paid to standardization and reproducibility of technology in the manufacturing process, which is an undeniable advantage of this remedy, taking account of a great variability of plant ingredients.

The main pharmacological effect based on the nephroprotective properties of BNO 2103, is most likely anti-inflammatory. It is known that rosemary acid, which is the main ingredient of BNO 2103, inhibits nonspecific activation of complement and lipoxigenase, and, as a consequence, the synthesis of leukotrienes, as well as breaks the chain of free radical reactions [16].

Diterpenes and polyphenols in rosemary leaves have antioxidant, antibacterial, antiviral, anti-inflammatory activity [17]. Furancummarins of lovage root were shown to have antispasmodic and diuretic effects, so they are used for irrigation therapy in inflammatory processes of the lower urinary tract [18,19].

These data are confirmed by studies of Wagenlehner, Nausch et al., which showed a positive therapeutic effect of the test drug on infectious and inflammatory processes of the urinary tract [20,21].

Significant anti-adhesive and anti-inflammatory activity of Canephron® N was also demonstrated in an in vitro and in vivo study by G. Künstle et al. [22].

In a non-interventional prospective clinical study evaluating the use of Canephron® N in pediatric practice, the drug was administered to more than a half of patients as monotherapy for cystitis, pyelonephritis, nephritis, and other urinary tract diseases, and 65 % showed improvements in condition, and 20 % – complete recovery, which also proves the significant anti-inflammatory properties of the drug [23].

Data from a clinical study including 30 patients with chronic calculous prostatitis receiving Canephron® N in addition to extracorporeal shock wave therapy, indicate remarkable symptomatic and anti-inflammatory effects of the drug with excellent compliance with therapy for 90 days [24].

Since the main goal of our research was to substantiate the use of BNO 2103 in the treatment of CKD, the objectives of the study were designed to investigate the nephroprotective, anti-inflammatory, diuretic, hypoazotemic, antiproteinuric effects of BNO 2103. Thus, the first goal was to study the BNO 2103 effect on the course of RF in rats in the model of chromate – induced RF. The second task was to examine the AIA of the active ingredients of the test drug in the model of phlogosis – induced paw inflammation in rats. According to the study results in the model of RF using laboratory and histomorphological methods, it was proved that the composition BNO 2103 has nephroprotective, diuretic, hypoazotemic and antiproteinuric effects and is superior to comparator drugs in most respects [25]. This article presents the results of the second stage of the study – to examine the anti-inflammatory activity of the test drug. Thus, the evidence base is gradually taking shape to build a strong argument for the expansion of indications for the use of BNO 2103 in the treatment of CKD.

A study on the BNO 2103 potential effect on cyclooxygenase – mediated inflammatory pathways using other types of phlogogens (carrageenan, prostaglandin
Conclusions

Therefore, experimental studies have shown that:

1. The combined herbal composition BNO 2103 has a significant anti-inflammatory effect, exerting an inhibitory effect on exudative inflammation caused by various phlogogens (zymosan, histamine, serotonin).

2. The presence of flavonoids in the composition most likely causes the predominant effect on the lipoxygenase pathway of arachidonic acid conversion, resulting in anti-inflammatory activity.

3. BNO 2103 can be considered as a promising antiphlogistic agent for the correction of inflammatory renal pathology due to its antileukotriene activity and inhibitory effect on the lipoxygenase pathway of arachidonic acid conversion, and therefore on the development of inflammatory reaction, that is very useful in the treatment of CKD, as inflammation is an integral part of its pathogenesis.

Prospects for further research. Further clinical studies are needed to confirm the obtained results and provide a basis for their implementation in real clinical practice.

Acknowledgments

The authors are grateful to Bionorica SE (Germany) for material supply and providing of the substance, and to the staff and managers of NIAPhU (Kharkiv, Ukraine), Department of Clinical Pharmacology and Clinical Pharmacy of NUPh (Kharkiv, Ukraine) for providing material and technical base for the research.

Conflict of interest: authors declare no conflict of interest.

Information about authors:

Chernyk V. V., MD, Postgraduate student of the Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine. ORCID ID: 0000-0003-2023-5792

Zupanets I. A., MD, PhD, DSc, Professor, Director of Clinical and Diagnostics Center of National University of Pharmacy, Kharkiv, Ukraine, Honored Worker of Science and Technology of Ukraine. ORCID ID: 0000-0002-8762-0056

Shebeko S. K., PhD, DSc, Associate Professor, Professor of the Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine. ORCID ID: 0000-0001-9350-7588

References

[1] Höller, M., Steindl, H., Abramov-Sommariva, D., Wagenlehner, F., Naber, K. G., & Kostew, K. (2021). Treatment of Urinary Tract Infections with Caseopenhagen in Germany: A Retrospective Database Analysis. Antibi-tiotics, 10(6), Article 685. https://doi.org/10.3390/antibiotics10060685
[2] Rechberger, E., Rechberger, T., Waaraviluki, S., Motta, P., Kulik-Rechberger, B., Kuska, A., & Wrobel, A. (2021). Randomized klinische vypobudzania dla otaczania efektywny Kanefronu n porovnanyo iz tryprofoksasyotom dla profilaktyky piłkoaparatsiyh infektili rynzhnikh sechovych shliakhiv (RANRA) i dosvitny vlozeno shvani vlastlivosti suburetralnogo silnika [Randomized Clinical Trial to Evaluate the Effect of Canephron N in Comparison to Ciprofloxacine in the Prevention of Postoperative Lower Urinary Tract Infections after Midurethral Sling Surgery]. Zdorove muzhchyni, (3), 43-48. https://doi.org/10.3804/2307-5090.2020.225569 [in Ukrainian].
[3] Kaneftonit H (Kaneftonit N). (n.d.). Kompendium OnLine. https://compendium.com/ru/de/269484/
[4] Slivak, K. V., Lesiesovskaia, E. E., Stomcan, K. I., & Savateeva-Lubimova, T. N. (2016). Efficiency of Canephron N in complex treatment of experimental heymann glomerulonephritis. Clinical Phytoscience, 2(1), Article 5. https://doi.org/10.1007/978-40816-015-092-8
[5] GBD Chronic Kidney Disease Collaboration. (2020). Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 395(10225), 709-733. https://doi.org/10.1016/S0140-6736(20)30045-3
[6] Canadian Council on Animal Care. (n.d.). General Guidelines. Caac.ca. https://caac.ca/evac/c/cas/guidelines/general-guidelines.html
[7] Suckow, M., Hankerson, F. C., Wilson, R., & Foley, P. (Eds.). (2019). The Laboratory Rat (3rd ed.). Academic Press. https://doi.org/10.1016/ C2017-0-1188-6
[8] EUR-lex. (2010). Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Europa.eu. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32010L0063
[9] Altmann, R., Bosch, B., Brune, K., Patrignani, P., & Young, C. (2015). Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology. Drugs, 75(8), 659-677. https://doi.org/10.1007/01000-015-0392-2
[10] Vogel, H. G. (Ed.). (2006). Drug Discovery and Evaluation (3rd ed.). Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-70995-4
[11] Sigurd, Ya. A., Shevartz, G. Ya., Liberman, S. S., & Arzama-stev, A. P. (1988). Lekarstvennaya terapiya vospeit/ego protoseya (eksperimental'naya i klinicheskaya farmakologiya protivovospeit/elt/nykh preparatov) [Drug therapy of inflammatory process (Experimental and clinical pharmacology of antiinflammatory drugs)]. Meditsina. [in Russian].
[12] U.S. Food and Drug Administration. (2005, July 6). Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-articles-and-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeu-tics-adult-healthy-volunteers
[13] Stelianou, A. V. (Ed.). (2001). Doklinichini doslidzhennia likarskikh zasobiv [Preclinical studies of drugs]. Avtsera. [in Ukrainian].
[14] Ismail, M. A., & Al-Shihaa, A. (2018). Foundations of Biostatistics. Springer Singapore. https://doi.org/10.1007/978-981-10-8672-4
[15] Litovsky, V. F. (2021). Efficacy of an herbal preparation based on lovage, rosemary, and centaury on patients after extracorporeal shock-wave lithotripsy. Clinical Phytoscience, 7(1). Article 10. https://doi.org/10.1007/s40816-021-00247-7
[16] Ma, Z., Lu, Y., Yang, F. U. S., He, X., Gao, Y., Zhang, G., Ren, E., Wang, Y., & Yang, K. (2020). Rosmarin acid exerts a neuroprotective effect on spinal cord injury by suppressing oxidative stress and...
inflammation via modulating the Nrf2/HO-1 and TLR4/NF-κB pathways. Toxicology and Applied Pharmacology, 397, Article 115014. https://doi.org/10.1016/j.taap.2020.115014

[17] Colica, C., Di Renzo, L., Aiello, V., De Lorenzo, A., & Abenavoli, L. (2018). Rosmarinic Acid as Potential Anti-Inflammatory Agent. Reviews on Recent Clinical Trials, 13(4), 240-242. https://doi.org/10.2174/15749087130418090990180

[18] Petrović, S. (2019). Herbal and traditional Herbal Medicinal Products, EU Herbal monographs and EU list. Arhiv Za Farmaciju, 69(4), 221-269. https://doi.org/10.5937/arfarm1904221p

[19] Nausch, B., Rohrl, J., Koeberle, A., Harter, U., Joannidis, M., Wierz, O., & Künstle, G. (2017). Canephron® N reduced immune cell recruitment in experimental cystitis. European Urology Supplements, 16(3), e230-e231. https://doi.org/10.1016/j.eus.2016.11.020-4

[20] Wagenlehner, Florian M., Abramov-Sommariva, D., Röhr, M., Steind, H., & Naber, Kurt G. (2016). Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urologia Internationalis, 101(3), 327-336. https://doi.org/10.1159/000493368

[21] Nausch, B., Pace, S., Pein, H., Koeberle, A., Rossi, A., Künstle, G., & Wierz, O. (2019). The standardized herbal combination BNO 2103 contained in Canephron® N alleviates inflammatory pain in experimental cystitis and prostatitis. Phytomedicine, 60, Article 152987. https://doi.org/10.1016/j.phymed.2019.152987

[22] Künstle, G., Brenneis, C., & Haunschmid, J. (2013). Efficacy of Canephron® N against bacterial adhesion, inflammation and bladder hyperactivity. European Urology Supplements, 12(1), e671. https://doi.org/10.1016/s1569-9056(13)61153-7

[23] Dlin, V. V., Abramov-Sommariva, D., Zakharova, I. N., Erman, M. V., Nazastushcheva, T. L., Kirov, V. L., Averyanova, N. I., Bereyanko, T. I., Letfiov, G. M., Vyatkova, A. A., Margieva, T. V., Morozov, S. L., & Kolchenko, I. I. (2018). A non-interventional, prospective, multicenter study for evaluation of the use of the herbal medicinal product Canephron® N in the pediatric outpatient population in Russia. Clinical Phytoscience, 4(1), Article 31. https://doi.org/10.3390/scipharm88040047

[24] Gorynchenko, I. I., & Spiridonenko, V. V. (2017). Efektivnost’ fitoterapii na fone primereniyavextrakorporal’noi udarno-volnovoi terapii u lits s khronicheskim kal’kuleznym prostatitom [The effectiveness of phytotherapy against the background of the use of extracorporeal shock wave therapy in persons with chronic calculus prostatitis]. Zdorov’e muzhchiny, (2), 29-24. https://doi.org/10.30841/2307-0090.2(61).2017.115926 [in Russian].

[25] Shebeko, S. K., Chernyk, V. V., & Zupanets, K. O. (2020). Nephro-protective Effect of the Herbal Composition BNO 2103 in Rats with Renal Failure. Scientia Pharmaceutica, 88(4), Article 47. https://doi.org/10.3390/scipharm88040047